Interest Coverage Ratio: 23.43x
Is the interest coverage ratio high or low?
The interest coverage ratio of 23.43x is in line with its 5-year average of 21.51x, around the middle of its 5-year range (-10.96x–58.68x).
As of Saturday, June 27, 2026. 60.29% above its 12-month average of 14.62x.
TECH Interest Coverage Ratio
Reported quarterly interest coverage; no daily interpolation.
TECH Average Interest Coverage Ratio Chart
TECH Current vs Average Interest Coverage Ratio Chart
TECH Interest Coverage Ratio Metrics
INTEREST COVERAGE RATIO
23.43x
INTEREST COVERAGE RATIO AVG TTM
14.62x
INTEREST COVERAGE RATIO AVG 3Y
18.66x
INTEREST COVERAGE RATIO AVG 5Y
21.26x
INTEREST COVERAGE RATIO AVG 10Y
16.31x
INTEREST COVERAGE RATIO AVG 15Y
N/A
INTEREST COVERAGE RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+60.29%
CURRENT VS 3Y AVG
+25.59%
CURRENT VS 5Y AVG
+10.19%
CURRENT VS 10Y AVG
+43.64%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
TECH Competitors' Interest Coverage Ratio
| NAME | MARKET CAP | INTEREST COVERAGE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bio-Techne Corporation (TECH) | $11.12B | 23.43x | 14.62x | 18.66x | 21.26x |
| Insulet Corp. (PODD)vs › | $10.96B | 5.94x | 6.59x | 5.07x | 3.90x |
| Baxter International Inc. (BAX)vs › | $11.38B | -1.06x | 0.71x | 2.65x | 6.89x |
| Molina Healthcare, Inc. (MOH)vs › | $11.79B | 4.07x | 9.27x | 11.38x | 10.77x |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | -29.20x | 3.03x | 3.75x | 5.52x |
| Charles River Laboratories International, Inc. (CRL)vs › | $10.20B | 4.74x | 3.27x | 5.51x | 5.84x |
| Tempus AI, Inc. (TEM)vs › | $9.80B | -3.40x | N/A | N/A | N/A |
| Henry Schein, Inc. (HSIC)vs › | $9.68B | 5.05x | 5.30x | 10.04x | 14.14x |
| Revvity, Inc. (RVTY)vs › | $12.61B | 3.87x | 4.06x | 4.92x | 8.88x |
| Align Technology, Inc. (ALGN)vs › | $12.78B | N/A | 67.41x | 66.08x | 407.22x |
Financial Health Indicators
Interest Coverage
23.4x
Debt/Equity
0.23
Current Ratio
3.46
Formula: Interest Coverage = EBIT / Interest Expense
Reference ranges:
- < 1.5x: EBIT is less than 1.5 times interest expense
- 1.5x - 3x: EBIT is between 1.5 and 3 times interest expense
- 3x - 5x: EBIT is between 3 and 5 times interest expense
- > 5x: EBIT is more than 5 times interest expense
Note: Interest coverage should be compared with historical interest expense, operating income, and industry capital structure.
Interest Coverage Ratio Formula & Definition
Interest Coverage = EBIT / Interest Expense
The interest coverage ratio measures operating earnings relative to interest expense.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Interest Coverage Ratio FAQ
- What is the interest coverage ratio for Bio-Techne Corporation (TECH)?
- The interest coverage ratio for TECH stock is 23.43x.
- Is Bio-Techne Corporation's interest coverage ratio high or low?
- The interest coverage ratio of 23.43x is in line with its 5-year average of 21.51x, around the middle of its 5-year range (-10.96x–58.68x).
- What is the TTM average interest coverage ratio for Bio-Techne Corporation (TECH)?
- The TTM average interest coverage ratio for TECH stock is 14.62x.
- What is the 3Y average interest coverage ratio for Bio-Techne Corporation (TECH)?
- The 3Y average interest coverage ratio for TECH stock is 18.66x.
- What is the 5Y average interest coverage ratio for Bio-Techne Corporation (TECH)?
- The 5Y average interest coverage ratio for TECH stock is 21.26x.
- What is the 10Y average interest coverage ratio for Bio-Techne Corporation (TECH)?
- The 10Y average interest coverage ratio for TECH stock is 16.31x.
TECH Interest Coverage Ratio History
| DATE | INTEREST COVERAGE RATIO |
|---|---|
| 2026-03-31 | 23.43x |
| 2025-12-31 | 25.09x |
| 2025-09-30 | 16.24x |
| 2025-06-30 | -10.96x |
| 2025-03-31 | 19.29x |
| 2024-12-31 | 22.08x |
| 2024-09-30 | 18.38x |
| 2024-06-30 | 18.26x |
| 2024-03-31 | 16.73x |
| 2023-12-31 | 8.78x |
| 2023-09-30 | 11.42x |
| 2023-06-30 | 25.53x |
| 2023-03-31 | 58.68x |
| 2022-12-31 | 28.82x |
| 2022-09-30 | 14.86x |
| 2022-06-30 | 32.16x |
| 2022-03-31 | 36.28x |
| 2021-12-31 | 21.48x |
| 2021-09-30 | 18.55x |
| 2021-06-30 | 20.84x |
| 2021-03-31 | 25.80x |
| 2020-12-31 | 14.22x |
| 2020-09-30 | 11.12x |
| 2020-06-30 | 8.51x |
| 2020-03-31 | 10.65x |
| 2019-12-31 | 7.59x |
| 2019-09-30 | 6.38x |
| 2019-06-30 | 7.73x |
| 2019-03-31 | 8.62x |
| 2018-12-31 | 5.83x |
| 2018-09-30 | 4.92x |
| 2018-06-30 | 14.06x |
| 2018-03-31 | 16.83x |
| 2017-12-31 | 10.36x |
| 2017-09-30 | 11.61x |
| 2017-06-30 | 19.20x |
| 2017-03-31 | 15.32x |
| 2016-12-31 | 8.40x |
| 2016-09-30 | 18.17x |
| 2016-06-30 | 92.41x |
| 2016-03-31 | 97.16x |
| 2015-12-31 | 90.06x |
| 2015-09-30 | 68.80x |
| 2015-06-30 | 97.43x |
| 2015-03-31 | 95.23x |
| 2014-12-31 | 79.13x |
| 2014-09-30 | 113.23x |
About Bio-Techne Corporation
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Kim Kelderman